KROS.US Keros Therapeutics Inc

Healthcare Biotechnology USA Stocks
10.30 USD
Close of Nov 15, 2026
8.98 22.55
Market cap
USD 202M
P/E
-
P/B
0.73x
ROE
-18.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is KROS.US undervalued?

Graham number

The Graham number of Keros Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Keros Therapeutics Inc fundamental analysis

No fundamental analysis for Keros Therapeutics Inc yet.

Keros Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Keros Therapeutics Inc

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and …

Full company profile